Ivermectin Safety Profile: What Studies Report
Updated: Sep 29
Written by Dr. Charles Drew, Lead Pharmaceutical Content Specialist & Clinical Drug Information Reviewer Reviewed for medical accuracy under the Ivermectinkart Editorial Policy
Introduction
The ivermectin safety profile is generally favorable when human formulations are used for established parasitic infections at recommended doses, but that conclusion has important limits. Clinical studies have most often reported mild, short-lived effects such as dizziness, nausea, diarrhea, itching, or fatigue, while rare serious neurological, skin, liver, and blood-pressure reactions have also been reported. In some parasitic infections, especially onchocerciasis, symptoms after treatment can partly reflect the body’s inflammatory response to dying parasites rather than direct drug toxicity. Higher-dose studies have not shown a clear overall increase in adverse events, but the available evidence is too limited to establish that unapproved higher doses are safe. Pregnancy, certain parasitic co-infections, drug interactions, and the use of veterinary formulations create additional safety concerns. This review looks at what clinical trials, systematic reviews, drug labeling, pharmacovigilance data, and recent research actually report—and where uncertainty remains
What Does the Ivermectin Safety Profile Show in Standard Human Use?
For its established human antiparasitic uses, ivermectin has decades of clinical experience and a relatively wide therapeutic margin. In the United States, oral ivermectin is labeled for intestinal strongyloidiasis and onchocerciasis, while other human formulations have different approved uses. The current U.S. ivermectin prescribing information describes safety findings from controlled and open-label studies as well as post-marketing reports.
Ivermectin works mainly by disrupting chloride channels that are important to the nerves and muscles of susceptible parasites. Mammals do not have the same glutamate-gated chloride channels, ivermectin has relatively low affinity for related mammalian channels, and it does not readily cross the human blood-brain barrier under ordinary circumstances. These differences help explain why therapeutic human doses can affect parasites without normally producing comparable neurological effects in people.
That does not mean the medicine is risk-free. Safety data collected for one disease, dose, or formulation cannot automatically be applied to another setting. A single prescribed treatment for a confirmed parasite infection is a different exposure from repeated self-dosing, very high dosing, or using a concentrated animal product.
What Side Effects Were Seen in Clinical Studies?
At standard oral doses, most drug-related adverse effects reported in trials were mild and relatively uncommon. In four strongyloidiasis studies involving 109 patients receiving one or two doses of 170–200 micrograms per kilogram, reported drug-related effects included dizziness in 2.8%, itching in 2.8%, nausea and diarrhea in 1.8% each, and several other symptoms in fewer than 1% of participants.
Onchocerciasis requires a different interpretation. In trials involving 963 adults, itching, rash, swelling, fever, and tender lymph nodes were frequently reported after treatment, but many of these are considered Mazzotti-type reactions—an inflammatory response associated with the death of microfilariae, the immature parasites. This means an event occurring after ivermectin is not necessarily caused solely by ivermectin itself.
What major types of ivermectin safety evidence report
Evidence source | What was studied | What researchers reported | Important limitation |
Strongyloidiasis clinical studies | 109 patients receiving standard human doses | Mostly mild gastrointestinal, skin, and neurological symptoms; dizziness and itching were each reported in 2.8% | Small sample and specific parasitic disease |
Onchocerciasis clinical studies | 963 adults receiving 100–200 mcg/kg | Drug-related edema, postural hypotension, and rapid heartbeat occurred in a minority; inflammatory parasite-killing reactions were more common | Disease itself contributes to many post-treatment symptoms |
High-dose controlled study | 68 healthy adults, including single doses up to 120 mg | Adverse experiences were similar to placebo and did not increase clearly with dose | Small study in healthy adults; not proof that high doses are appropriate for routine use |
High-dose systematic review | Six eligible studies | No clear overall difference in adverse-event frequency or severity between standard and higher doses | Evidence was insufficient to recommend doses above approved regimens |
Pharmacovigilance research | International reports of suspected serious reactions | Neurological and severe skin-event signals were identified | Spontaneous reports cannot establish incidence or prove causation |
2026 pregnancy analysis | 238 pregnancies around ivermectin or albendazole exposure | No statistically significant difference in adverse pregnancy outcomes was detected | Wide confidence intervals and limited sample mean meaningful differences cannot be excluded |
What Do Higher-Dose Studies Tell Us About Safety?
Higher-dose research is reassuring in some respects, but it does not establish that taking more ivermectin is generally safe. A double-blind, placebo-controlled study of 68 healthy adults tested single doses as high as 120 mg and repeated regimens of 30 or 60 mg. Researchers reported no clear dose-related increase in adverse experiences and no indication of central nervous system toxicity in that small study.
A later systematic review of high-dose ivermectin safety evaluated six studies and similarly found no overall increase in the number of participants experiencing adverse events or in their severity at higher doses. However, the authors specifically concluded that the available data were not sufficient to recommend higher-than-approved doses. An increase in transient ocular events was also observed in one higher-dose onchocerciasis study.
This distinction matters. A study can fail to detect additional harm because a treatment truly has similar safety—or because the study is too small to detect uncommon problems. Rare neurological, severe skin, liver, or cardiovascular events usually require much larger populations and post-marketing surveillance to identify reliably.
A small trial showing that higher doses were tolerated does not prove that higher doses are safe for routine self-use. The strongest safety evidence remains tied to studied human formulations, particular indications, and defined dosing regimens.
What Rare or Serious Adverse Events Have Been Reported?
Serious reactions appear uncommon relative to ivermectin's extensive therapeutic use, but they are clinically important. Current U.S. labeling includes post-marketing reports of seizures, severe skin reactions such as Stevens-Johnson syndrome and toxic epidermal necrolysis, hepatitis or abnormal liver tests, significant hypotension, and neurotoxicity involving confusion, marked drowsiness, stupor, coma, and death. A post-marketing report signals that an event occurred after treatment; it does not by itself establish how often the event occurs or prove ivermectin caused every case.
Neurological safety has received particular attention. A WHO VigiBase pharmacovigilance analysis identified disproportionate reporting of encephalopathy and confusional disorders after ivermectin compared with some other antiparasitic drugs. The researchers emphasized continued pharmacovigilance while noting that spontaneous-report databases are vulnerable to underreporting, reporting bias, missing clinical information, and uncertainty about causation.
Liver injury is another example where wording matters. NIH LiverTox describes minor, self-limited liver-enzyme elevations and very rare clinically apparent liver injury associated with ivermectin; it characterizes ivermectin as a possible rare cause of mild clinically apparent liver injury rather than a common hepatotoxic drug.
Who Needs Extra Caution With Ivermectin?
Safety is not identical for every person. Pregnancy, very young children, certain parasite exposures, interacting medicines, and significant underlying illness can change the risk-benefit assessment.
Pregnancy and breastfeeding
Pregnancy evidence remains incomplete. A 2020 systematic review found that available human studies were insufficient to determine whether ivermectin changes the risk of miscarriage, stillbirth, or congenital abnormalities, with the certainty of evidence rated very low.
More recently, a 2026 pregnancy safety analysis evaluated women potentially exposed around conception in trials in Mozambique and Kenya. Among pregnancies with evaluable outcomes, adverse outcomes occurred in 24 of 105 ivermectin-exposed pregnancies and 15 of 77 albendazole-exposed pregnancies; the difference was not statistically significant, but the confidence interval was wide enough that a meaningful difference in either direction could not be ruled out.
The current U.S. oral product label states that adequate well-controlled studies in pregnant women are lacking and that safety in pregnancy has not been established. Decisions involving pregnancy or breastfeeding therefore require professional assessment rather than extrapolation from general adult safety data.
Loa loa exposure
One of the best-established special risks occurs in people with heavy Loa loa infection. Rare, severe encephalopathy—including confusion, difficulty walking, seizures, coma, and death—has occurred after microfilaricidal treatment in heavily infected individuals. The U.S. label advises pretreatment assessment for loiasis when a patient needing ivermectin has had significant exposure in Loa loa-endemic parts of West or Central Africa.
Children, older adults, and medicine interactions
For the U.S. oral product, safety and effectiveness have not been established in children weighing less than 15 kg. Clinical trials also included too few adults aged 65 or older to determine whether they respond differently, so factors such as liver, kidney, or heart function and other medicines become particularly relevant.
The label additionally notes rare reports of increased INR—a laboratory measure of blood clotting—when ivermectin was given with warfarin. Anyone taking anticoagulants or several prescription medicines should therefore have potential interactions reviewed by a clinician or pharmacist rather than assuming ivermectin has no interaction risk.
Why Do Formulation, Indication, and Self-Medication Change the Risk?
A medicine's safety profile applies to the formulation and exposure that were actually studied. Veterinary ivermectin products can contain different concentrations or inactive ingredients and are designed for animals, not people. Using an animal product can therefore create dosing and toxicity risks that human clinical trials do not address.
The FDA ivermectin safety guidance states that veterinary ivermectin products should not be used in humans and reports that some people have required medical care, including hospitalization, after self-medicating with animal formulations. The agency also warns that large ivermectin doses can cause vomiting, low blood pressure, balance problems, seizures, coma, and death.
The same principle applies to unapproved indications. Evidence that ivermectin is reasonably well tolerated when prescribed for a particular parasitic infection does not demonstrate that repeated or high-dose treatment is safe—or effective—for unrelated diseases. For example, the FDA has not authorized or approved ivermectin to prevent or treat COVID-19 and states that available clinical trial evidence does not demonstrate effectiveness for that use.
When Should You Seek Medical Care?
Most mild effects such as temporary nausea, diarrhea, dizziness, or itching do not automatically indicate serious toxicity. However, symptoms involving the brain, breathing, circulation, severe skin reactions, or possible liver injury deserve prompt medical evaluation, particularly when symptoms are intense or worsening.
Ivermectin symptoms and the level of medical attention they may require
Situation | Examples | Practical response |
Mild, short-lived symptoms | Nausea, mild diarrhea, dizziness, itching, fatigue | Contact the prescribing clinician if symptoms persist, worsen, or are difficult to tolerate |
Possible allergic or severe skin reaction | Facial swelling, breathing difficulty, widespread blistering, peeling skin | Seek urgent medical care |
Possible neurological toxicity | Severe confusion, extreme drowsiness, inability to coordinate movement, seizure, loss of consciousness | Seek emergency medical care |
Significant cardiovascular symptoms | Fainting, severe weakness, symptoms of marked low blood pressure | Seek urgent medical assessment |
Possible liver problem | Yellowing of the skin or eyes, dark urine, persistent abdominal symptoms with illness | Contact a clinician promptly |
Suspected overdose or veterinary-product exposure | Large or uncertain dose, concentrated animal formulation, significant symptoms after exposure | Contact emergency or poison-control services promptly |
If severe symptoms occur after ivermectin, do not take additional doses while trying to determine the cause on your own. Bring the medication packaging or product information when seeking care, because formulation and concentration can materially affect assessment.
Conclusion
The ivermectin safety profile is best described as generally favorable for established human antiparasitic uses at studied doses, with most trial-reported effects being mild and temporary. However, rare neurological, skin, liver, and cardiovascular reactions exist, and evidence for higher doses, prolonged use, pregnancy, and some special populations remains more limited.
Safety also depends on the diagnosis, formulation, other medicines, and individual risk factors. Use ivermectin only in an appropriate human formulation and under qualified medical guidance. If you are considering ivermectin or have experienced unexpected symptoms after taking it, discuss the situation with a licensed clinician or pharmacist rather than changing the dose yourself.
Frequently Asked Questions
1 . Is ivermectin generally safe for humans?
Ivermectin is generally well tolerated when an appropriate human formulation is used for an established indication at a studied dose. Mild effects such as dizziness, nausea, diarrhea, or itching can occur. Rare serious neurological, skin, liver, and blood-pressure reactions have also been reported.
2 . What are the most common ivermectin side effects?
Reported effects include dizziness, itching, nausea, diarrhea, fatigue, and other gastrointestinal symptoms. The pattern varies with the disease being treated. With onchocerciasis, fever, rash, swelling, and itching may also result from inflammation triggered when parasites die after treatment.
3 . Can ivermectin cause neurological problems?
Yes, serious neurological reactions have been reported, although they appear uncommon relative to widespread therapeutic use. Reports include confusion, marked drowsiness, seizures, impaired consciousness, and coma. Heavy Loa loa infection is a recognized risk setting, but neurological reports have also occurred without it.
4 . Is high-dose ivermectin proven to be safe?
No. Small trials and a systematic review did not find a clear overall increase in adverse events at higher doses, but the evidence base was limited. Researchers specifically concluded that available safety data were insufficient to recommend ivermectin at doses above established regimens.
5 . Is ivermectin safe during pregnancy?
Its safety during pregnancy remains uncertain. Earlier systematic-review evidence was very low certainty, while a 2026 study found no statistically significant difference versus albendazole but could not exclude meaningful risk. Pregnancy-related treatment decisions should therefore be made with an appropriately qualified healthcare professional.
6 . Is long-term ivermectin use safe?
Long-term routine self-treatment is not supported by the same evidence base as established short-course antiparasitic treatment. Many safety studies examined single doses or limited treatment schedules. Repeated or prolonged use should therefore not be assumed safe simply because standard short-course treatment is generally well tolerated.
Comments